PulseSight Therapeutics is advancing an exciting pipeline of novel, minimally invasive, non-viral gene therapies designed to address major unmet medical needs in severe retinal diseases leading to blindness, with a primary focus on late-stage dry AMD/Geographic atrophy (GA) and wet AMD.
Age-related macular degeneration (AMD) is a leading cause of irreversible vision loss in the elderly, affecting 200 million people worldwide2.
We are pioneering a unique therapeutic approach using a proprietary electro-transfection delivery system to administer plasmid-based gene therapies into the ciliary muscle.
Our innovative platform enables sustained expression of therapeutic proteins, with the potential to offer effective treatment options with a clinically validated safety profile, reduced treatment burden, and improved patient compliance.
PulseSight’s two lead programs, PST-611 (dry AMD/GA) and PST-809 (wet AMD), build on over a decade of preclinical and clinical development, including Phase 1/2 studies conducted in Europe and the USA validating both the clinical relevance and safety of our non-viral gene therapy approach1.
Our technology is covered by a strong, globally established, intellectual property portfolio, reinforcing its long-term value and competitive differentiation.
1Hoogewoud et al. EYS606 for the Treatment of Non-Infectious Uveitis Acta Ophthalmologica 99(3): 343 (2019)
2Wong WL, Su X, Li X, Cheung CMG, Klein R, Cheng C-Y, et al.
Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014 Feb;2(2):e106–116. doi:10.1016/S2214-109X(13)70145-1. PMID: 25104651.